CRISPR Therapeutics (CRSP) News Today

Capital International Investors boosted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 27.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,837,074 shares o

Seven Eight Capital LP lessened its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 57.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,524 shares of the company's stock after se

Blair William & Co. IL lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 8.2% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 147,890 shares of the company's stock after purchasing an additional 11,

Entropy Technologies LP bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 25,280 shares of the company's stock, valued at approxim

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) saw a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 15,650,000 shares, an increase of 5.2% from the June 15th total of 14,870,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the days-to-cover ratio is currently 11.9 days.

SG Americas Securities LLC decreased its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 19.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,806 shares of the company's stock after

Susquehanna Portfolio Strategies LLC lowered its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 48.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,278 share

Susquehanna Fundamental Investments LLC acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,503 shares of the comp

CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 7.2%

Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume.

Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.

BNP Paribas Financial Markets lifted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 252.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 148,942 shares of the company's stock after purchas

Nordea Investment Management AB raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 40.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 148,700 shares of the company's stock after buyin

Mirae Asset Global Investments Co. Ltd. boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 86.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 166,546 shares of the comp

Baillie Gifford & Co. reduced its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 6.4% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 395,915 shares of the company's stock after selling 26,848 shares during the period. Baillie Gifford & Co. ow

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have earned a consensus rating of "Hold" from the eighteen research firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eight have issued a hold recomme

Principal Financial Group Inc. purchased a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 40,470 shares of the company's stock, valued at approximately $2,758

Sumitomo Mitsui Trust Holdings Inc. lowered its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 3.0% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,268,785 shares of the com

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) saw a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 14,870,000 shares, a decline of 5.0% from the May 31st total of 15,660,000 shares. Based on an average daily volume of 1,340,000 shares, the short-interest ratio is presently 11.1 days.

Foguth Wealth Management LLC. purchased a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 14,791 shares of the company's stock, val

CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 1.6%

CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 1%

CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.6%

CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 1.3% After Insider Selling

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) COO Julianne Bruno sold 3,366 shares of the stock in a transaction on Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the sale, the chief operating officer now owns 6,745 shares of the company's stock, valued at $378,327.05. The sale was disclosed in a filing with the SEC, which is available at this link.

CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 2.1%